Search Clinical Trials in the European Union

Duration
Visits
Phase
Intake methods
No Placebo
Drugs
Locations
Clinical Specialty
861-880 of 2,251 trials

Juvenile Idiopathic Arthritis: Bimekizumab Study

We are studying the safety and how bimekizumab moves in the body for children aged 2 to under 18 with certain types of juvenile idiopathic arthritis. This research aims to help improve treatment options for these young patients.

Juvenile Arthritis and Related Conditions6-12 monthsConfirmation phase (III)Post-Trial Drug AccessNo PlaceboStandard MedicinesPartially RemotePediatricsRheumatology

Non-Small Cell Lung Cancer: Neoadjuvant and Adjuvant Treatment Study

We are studying a new treatment approach for patients with resectable non-small cell lung cancer to see if it improves tumor response and safety before and after surgery.

Non-small Cell Lung Cancer (NSCLC)>2 yearsEfficacy phase (II)Post-Trial Drug AccessNo PlaceboInvestigational MedicinesCost ReimbursementOncologyPulmonology

Metastatic Colorectal Cancer: Tinzaparin for Blood Clot Prevention

We are studying whether tinzaparin can help prevent blood clots in patients with metastatic colorectal cancer starting their first line of treatment. This may help reduce the risk of complications related to blood clots.

Metastatic Colorectal CancerThromboembolic Event>2 yearsConfirmation phase (III)No PlaceboStandard MedicinesCardiologyOncology

Heart Failure: Finerenone and SGLT2 Inhibitor Study

We are investigating whether a combination of finerenone and an SGLT2 inhibitor can improve health outcomes for hospitalized heart failure patients. This study aims to see if this approach leads to better symptom relief and fewer hospital visits.

Heart Failure1-2 yearsConfirmation phase (III)No PlaceboStandard MedicinesCost ReimbursementPartially RemoteCardiologyInternal Medicine

Myeloid Malignancies: BGB-11417 Study

We are testing a new drug, BGB-11417, in combination with azacitidine for patients with myeloid malignancies. The goal is to find the safest dose and see how well it works against the disease.

Myeloid MalignanciesSafety phase (I)Efficacy phase (II)Post-Trial Drug AccessNo PlaceboInvestigational MedicinesHematologyInternal Medicine

Atrial Fibrillation: Rivaroxaban Monotherapy Study

We are exploring the safety of rivaroxaban in patients with atrial fibrillation who have had a heart procedure. This study aims to see if this treatment is a viable option for these patients.

Coronary Artery DiseasePercutaneous Coronary InterventionAtrial Fibrillation>2 yearsMonitoring phase (IV)No PlaceboStandard MedicinesCardiologyInternal Medicine

Prednisolone Transfer in Breast Milk: A Study for Breastfeeding Mothers

We are investigating how prednisolone, used for inflammation, transfers into breast milk and affects breastfeeding infants. This study aims to measure medication levels in both mothers and their babies to ensure safety.

Rheumatoid ArthritisSystemic Lupus ErythematosusMyositis≤3 monthsMonitoring phase (IV)No PlaceboStandard MedicinesInternal MedicinePediatrics

Advanced Lung Cancer: Adagrasib and Pembrolizumab Study

We are testing a new treatment combining adagrasib with pembrolizumab for patients with advanced non-small cell lung cancer with a KRAS G12C mutation. The goal is to see if this combination works better than pembrolizumab alone.

Advanced Non-Small Cell Lung CancerEfficacy phase (II)Confirmation phase (III)No PlaceboStandard MedicinesCost ReimbursementPartially RemoteOncologyPulmonology

Childhood Renal Tumors: Comparing Chemotherapy Treatments

We are studying two chemotherapy combinations for children with stage IV renal tumors to see which one works better and has fewer side effects. This research aims to improve treatment outcomes for young patients.

Nephroblastoma6-12 monthsConfirmation phase (III)No PlaceboStandard MedicinesNephrologyOncologyPediatrics

High-Grade Glioma in Children: Larotrectinib Treatment

We are studying the effects of larotrectinib on young children with newly diagnosed high-grade glioma that has an NTRK fusion. The trial will help us understand how well it works and its safety when used alone or with chemotherapy.

High Grade Glioma (HGG)>2 yearsEfficacy phase (II)No PlaceboStandard MedicinesOncologyPediatrics

HER2-Positive Breast Cancer: Zanidatamab vs. Trastuzumab

We are studying whether zanidatamab combined with chemotherapy is more effective and safer than trastuzumab with chemotherapy for patients with metastatic HER2-positive breast cancer who have not responded to previous treatments.

Metastatic HER2-positive Breast Cancer3-6 monthsConfirmation phase (III)No PlaceboInvestigational MedicinesCost ReimbursementOncology

Hypertrophic Cardiomyopathy: Aficamten Study

We are evaluating the long-term safety and tolerability of aficamten in adults with hypertrophic cardiomyopathy. The study also looks at its effects on heart function in patients with obstructive HCM.

Hypertrophic Cardiomyopathy1-2 yearsEfficacy phase (II)6-10 visitsPost-Trial Drug AccessNo PlaceboInvestigational MedicinesCardiologyInternal Medicine

Autoimmune Disease: Ianalumab Delivery Methods

We are comparing two ways to deliver ianalumab to adults with autoimmune diseases. This study will help us understand how well the medication works and its safety when given in different forms.

Sjögren's DiseaseRheumatoid ArthritisSystemic Lupus Erythematosus6-12 monthsEfficacy phase (II)No PlaceboInvestigational MedicinesPartially RemoteInternal MedicineRheumatology

Cardiac Device Implantation: Local vs. Regional Anesthesia

We are comparing local anesthesia with a specific regional block to see which provides better comfort for patients undergoing cardiac device implantation. This study also looks at any side effects and the need for extra pain relief.

Implantation of Cardiac Devices1-2 yearsMonitoring phase (IV)No PlaceboStandard MedicinesCardiologyInternal MedicineOtolaryngology

Pancreatic Cancer: Antiplatelet Therapy Study

We are investigating if adding an antiplatelet medication to standard care can help prevent blood clots in patients with pancreatic cancer. We also want to see if it may improve survival rates.

Pancreatic Ductal Cancer6-12 monthsConfirmation phase (III)6-10 visitsNo PlaceboStandard MedicinesPartially RemoteCardiologyOncology

Graft-Versus-Host Disease Prevention: CY-MET-RIC Study

We are testing two different treatment plans to see which better prevents severe graft-versus-host disease in patients receiving matched-donor transplants. This study will also evaluate overall survival and other important health outcomes.

Hematological Malignancies>2 yearsEfficacy phase (II)No PlaceboStandard MedicinesHematologyInfectious Diseases

Vedolizumab for Children with Moderate to Severe Crohn's Disease

We are studying how well different doses of vedolizumab help children and teenagers with Crohn's disease maintain their health. The goal is to see if it can keep symptoms under control and improve their overall well-being.

Crohn's Disease1-2 yearsConfirmation phase (III)Post-Trial Drug AccessNo PlaceboStandard MedicinesCost ReimbursementGastroenterologyPediatrics

Ulcerative Colitis and Crohn's Disease: Vedolizumab IV in Kids

We are studying the long-term safety of vedolizumab IV in children and teenagers with ulcerative colitis or Crohn's disease. This research aims to understand its effects on health and quality of life.

Active Ulcerative Colitis or Crohn's Disease>2 yearsConfirmation phase (III)>20 visitsPost-Trial Drug AccessNo PlaceboStandard MedicinesCost ReimbursementGastroenterology

Ivosidenib for Acute Myeloid Leukemia After Stem Cell Transplant

We are studying whether Ivosidenib can help patients with acute myeloid leukemia or high-risk myelodysplastic neoplasia stay healthy after a stem cell transplant. This trial focuses on those with an IDH1 mutation to see if it improves their chances of remaining disease-free.

Acute Myeloid Leukemia (AML)Myelodysplastic Neoplasia (MDS)>2 yearsEfficacy phase (II)No PlaceboStandard MedicinesHematologyOncology

Small Cell Lung Cancer: AL8326 Treatment Study

We are evaluating the safety and effectiveness of the drug AL8326 for patients with small cell lung cancer who have already received prior treatment. This study aims to find the best dose and understand how well the drug works.

Small Cell Lung Cancer>2 yearsEfficacy phase (II)6-10 visitsPost-Trial Drug AccessNo PlaceboInvestigational MedicinesOncologyPulmonology